In an initial trial of glibenclamide in the treatment of maturity onset diabetes mellitus 28 patients were treated for up to one year and no toxic effects or side-effects were encountered. The hypoglycaemic potency of this drug is such that 5 mg. of glibenclamide corresponds to about 1,500 mg. of tolbutamide and 375 mg. of chlorpropamide. © 1970, British Medical Journal Publishing Group. All rights reserved.
CITATION STYLE
Bhatia, S. K., Hadden, D. R., Montgomery, D. A. D., & Weaver, J. A. (1970). Glibenclamide Therapy in Diabetes Mellitus. British Medical Journal, 2(5709), 570–572. https://doi.org/10.1136/bmj.2.5709.570
Mendeley helps you to discover research relevant for your work.